ArticleLife science alliance2026
TRK-T3 condensate organization drives growth signaling.
Article in Life science alliance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Oncogenic fusion proteins involving receptor tyrosine kinases can hijack cell signaling cascades to promote oncogenesis. Here, we show that the TRK-T3 fusion protein, generated by joining the N-terminal region of the condensate-forming protein TFG with the C-terminal region of TrkA, assembles into sheet-like biomolecular condensates after putative prewetting of the ER. These structures are distinct from those formed by either parent protein. We find that ER wetting and the condensate morphology of TRK-T3 are controlled by a hydrophobic transmembrane segment encoded in the TrkA moiety. Removing this segment abolishes the sheet-like morphology of TRK-T3 condensates in cells and in vitro. This loss of morphology diminishes the recruitment of the first-layer signal-transduction protein GRB2 and suppresses activation of the MAPK pathway. A minimal segment that mimics the transmembrane domain efficiently disrupts TRK-T3 condensation. Together, our findings highlight condensate morphology as an encoded property of this oncogenic fusion protein, controlling the alignment and signaling competence of TRK-T3 assemblies. They further suggest that hydrophobic interactions within TRK-T3 condensates represent a potential vulnerability in this oncogenic signaling mechanism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.